NASDAQ Companies

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights […]

— Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data […]

Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce […]

CHINO, Calif., March 01, 2024 (GLOBE NEWSWIRE) — Karat Packaging Inc. (“Karat” or the “Company”) (Nasdaq: KRT), a specialty distributor […]

Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and […]

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage […]

CUPERTINO, CA, March 01, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX) announced that the company will […]

HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused […]

– Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 – – […]

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology […]